Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nisoldipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 10/20 | 0.98 |
| ▸ | CACNA1F known ✓ | O60840 | 9/20 | 0.98 |
| ▸ | CACNA1D known ✓ | Q01668 | 9/20 | 0.98 |
| ▸ | CACNA1S known ✓ | Q13698 | 9/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.98 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.98 |
| ▸ | SCN1A | P35498 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.98 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.98 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nisoldipine SCHEMBL29420725 | 0.99 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL39779 | 0.99 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL39780 | 0.99 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL19348996 | 0.99 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL1172989 | 0.99 | CACNA1C (1.00) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL3855961 | 0.98 | CACNA1C (0.98) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| Nisoldipine SCHEMBL27608147 | 0.98 | CACNA1C (0.98) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| SCHEMBL4608536 | 0.95 | CACNA1D (0.92) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| SCHEMBL9765770 | 0.92 | CACNA1C (0.86) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 | |
| SCHEMBL7432246 | 0.91 | CACNA1C (0.84) | CACNA1CCACNA1FCACNA1DCACNA1SADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389534-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2022-07-19 | — | — | US | disclosed |
| US-10946197-B2 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200360271-A1 | Methods and Compositions for Treating a Renal Disease Condition in a Subject | Palo Alto Investors LP | 2020-11-19 | — | — | US | disclosed |
| US-10716749-B2 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS (US) | 2020-07-21 | — | — | US | disclosed |
| US-10086071-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2018-10-02 | — | — | US | disclosed |
| US-20160367807-A1 | Treatment of Conditions Through Modulation of the Autonomic Nervous System | PALO ALTO INVESTORS | 2016-12-22 | — | — | US | disclosed |
| US-20160008387-A9 | AGENTS AND DEVICES FOR AFFECTING NERVE FUNCTION | NORTHWIND MEDICAL, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20150132409-A1 | AGENTS AND DEVICES FOR AFFECTING NERVE FUNCTION | NORTHWIND MEDICAL INC (US) | 2015-05-14 | — | — | US | disclosed |
| US-20140086872-A1 | Methods of Treating a Subject for a Condition | PALO ALTO INVESTORS (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2013169741-A1 | AGENTS AND DEVICES FOR AFFECTING NERVE FUNCTION | STEIN EMILY A (US) | 2013-11-14 | — | — | WO | disclosed |
| US-7738952-B2 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100119482-A1 | Treatment of Conditions Through Modulation of the Autonomic Nervous System During at Least One Predetermined Menstrual Cycle Phase | PALO ALTO INVESTORS | 2010-05-13 | — | — | US | disclosed |
| US-7363076-B2 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2008-04-22 | — | — | US | disclosed |
| US-20080004596-A1 | DELIVERY OF AGENTS BY MICRONEEDLE CATHETER | PALO ALTO INSTITUTE (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070112327-A1 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS | 2007-05-17 | — | — | US | disclosed |
| US-20060034847-A1 | Methods of treating a subject for a condition | PALO ALTO INVESTORS | 2006-02-16 | — | — | US | disclosed |
| US-20050256028-A1 | Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase | PALO ALTO INVESTORS | 2005-11-17 | — | — | US | disclosed |
| US-20050240241-A1 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS | 2005-10-27 | — | — | US | disclosed |
| US-20050153885-A1 | administering aldosterone antagonists such as spironolactone and eplerenone, to increasing the parasympathetic and sympathetic activity | PALO ALTO INVESTORS | 2005-07-14 | — | — | US | disclosed |
| US-20050021092-A1 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS | 2005-01-27 | — | — | US | disclosed |